Slide 1: Genetic Medicines for High Unmet Medical Needs
Genetic Medicines for High Unmet Medical Needs JPM 2026 © Copyright 2026 Krystal Biotech, Inc. All rights reserved.
Slide 2: Forward Looking Statements and Disclosures
Forward Looking Statements and Disclosures Forward Looking Statements This presentation and our discussion contain forward-looking statements that involve substantial risks and uncertainties. Any statements about future expectations, plans, and prospects for Krystal Biotech, Inc. (together with its
Slide 3: Global VYJUVEK Launch
Global VYJUVEK Launch 2H 2025 Approval and launch in France, Germany, and Japan 2023 First launch in Over 1.3K the United States Identified DEB Patients Across All Three Markets Over 1.2K Identified DEB Patients in the United States* + distribution agreements also now in place for over *Estimated To
Slide 4: Fully Integrated with Strong Financial Foundation
Fully Integrated with Strong Financial Foundation Over $729M 175K+ sq ft Combined size of Krystal’s two U.S. cGMP VYJUVEK Net Revenue manufacturing facilities Since Launch* $106 $96.0 $97.8 to $91.1 $88.2 $107* $83.8 ANCORIS: 20K+ sq ft ASTRA: 150K+ sq ft $70.3 $955M $42.1 $45.3 Approximate cash and
Slide 5: Krystal's Vision for 2030
Krystal’s Vision for 2030 4 Krystal Marketed Rare Disease 10,000+ Patients Treated with Krystal Rare Disease Medicines Medicines, Inclusive of VYJUVEK Krystal | 5
Slide 6: Deep Pipeline of Genetic Medicines That Leverage the Strengths of HSV-1
Deep Pipeline of Genetic Medicines That Leverage the Strengths of HSV-1 Indication Payload Preclinical Phase 1/2 Registrational Commercial U.S. Dystrophic epidermolysis bullosa (DEB) COL7A1 FDA, EMA, PMDA Approved Europe Japan Rare KB803 Ocular complications of DEB COL7A1 Disease Pipeline KB801 Neur
Slide 7: The Next Four Years Could Be Transformational for Krystal
The Next Four Years Could Be Transformational for Krystal Program Indication Estimated Prevalence Clinical Status Market Potential Ocular Complications KB803 1K+ in US and Europe Enrolling Registrational $300M+ of DEB KB801 Neurotrophic Keratitis 68K in the US Enrolling Registrational $1B+ Modulator
Slide 8: Building on our HSV-1 Advantage
Building on our HSV-1 Advantage FDA Platform Technology Designation granted 4Q 2025 ✓ Large cargo capacity ✓ Broad cellular tropism ✓ Flexible administration options ✓ Redosable ✓ Low immunogenicity and no integration risk Krystal’s engineered, replication-incompetent ✓ Scalable manufacturing HSV-1
Slide 9: KB803 for Treatment of Corneal Abrasions in DEB Patients
KB803 KB803 for Treatment of Corneal Abrasions in DEB Patients Krystal’s HSV-1 vector encoding COL7A1 for Registrational study readout expected in 2026 eye drop application Compassionate Use Case Visual Acuity in Treated Eye Ocular Disease Burden of DEB Treated Eye Visual Time Acuity ▪ Many DEB pati
Slide 10: KB801 for the Treatment of Neurotrophic Keratitis
KB801 KB801 for the Treatment of Neurotrophic Keratitis Krystal’s HSV-1 vector encoding NGF for eye Currently enrolling in upsized registrational study and expecting top-line data in 2026 drop application Head to Head Comparison of Eye NGF Neurotrophic Keratitis Levels in Wounded Cornea Model ▪ Dege
Slide 11: KB407 for the Treatment of Cystic Fibrosis
KB407 KB407 for the Treatment of Cystic Fibrosis Krystal’s HSV-1 vector encoding CFTR for Registrational study expected to start in 1H 2026 delivery via inhalation Cystic Fibrosis Successful Delivery and Expression of CFTR Confirmed in Class I CF Patient Lungs ▪ Progressive lung disease caused by mu
Slide 12: KB111 for the Treatment of Hailey-Hailey Disease
KB111 KB111 for the Treatment of Hailey-Hailey Disease Krystal’s HSV-1 vector encoding ATP2C1 for Registrational study expected to start in 2H 2026 topical application to skin • Hailey-Hailey disease (HHD) is a rare monogenic disease characterized by painful rash and blistering in skin folds • Preva
Slide 13: Clear Path to Building Shareholder Value in 2026 and Beyond
Clear Path to Building Shareholder Value in 2026 and Beyond Global VYJUVEK Clinical Pipeline Execution and Readouts Launch Execution ▪ KB803 Phase 3 readout for corneal abrasions in DEB patients ▪ KB801 registrational readout for neurotrophic keratitis ▪ Start and fully enroll registrational KB407 r
Slide 14: Developing Genetic Medicines to Treat Diseases with High Unmet Medical Needs
Developing Genetic Medicines to Treat Diseases with High Unmet Medical Needs © Copyright 2026 Krystal Biotech, Inc. All rights reserved.